Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
67046-1171-03 67046-1171 PREDNISONE Prednisone 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 5, 2026 In Use
68788-4113-06 68788-4113 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 8, 2026 In Use
68788-4113-01 68788-4113 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 8, 2026 In Use
68788-4113-05 68788-4113 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 8, 2026 In Use
68788-4113-03 68788-4113 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 8, 2026 In Use
00121-4882-94 00121-4882 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 9, 2026 In Use
00310-9501-04 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Jun 10, 2026 In Use
82249-0613-30 82249-0613 Everolimus Yulithira 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 11, 2026 In Use
82249-0612-30 82249-0612 Everolimus Yulithira 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 11, 2026 In Use
82249-0611-30 82249-0611 Everolimus Yulithira 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 11, 2026 In Use
68788-4133-01 68788-4133 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 11, 2026 In Use
68788-4133-03 68788-4133 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 11, 2026 In Use
82249-0610-30 82249-0610 Everolimus Yulithira 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 11, 2026 In Use
75907-0405-30 75907-0405 Bosutinib Bosutinib 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 12, 2026 In Use
87063-0224-05 87063-0224 Anastrozole Tablets Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jun 15, 2026 In Use
87063-0224-30 87063-0224 Anastrozole Tablets Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jun 15, 2026 In Use
87063-0224-60 87063-0224 Anastrozole Tablets Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jun 15, 2026 In Use
87063-0224-90 87063-0224 Anastrozole Tablets Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jun 15, 2026 In Use
67046-1242-03 67046-1242 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 16, 2026 In Use
71332-0007-30 71332-0007 Vepdegestrant VEPPANU 100.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral Jun 16, 2026 In Use
71332-0008-30 71332-0008 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral Jun 16, 2026 In Use
51407-0989-60 51407-0989 Abiraterone acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Jun 17, 2026 In Use
60505-6411-00 60505-6411 Hydrocortisone sodium succinate Hydrocortisone sodium succinate 100.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Jun 19, 2026 In Use
71390-0250-02 71390-0250 Pemetrexed Pemfexy 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jun 22, 2026 In Use
73536-0511-01 73536-0511 ROPEGINTERFERON ALFA-2B BESREMi Pen 500.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Jun 25, 2026 In Use

Found 12611 results — Export these results